文献速递骨质疏松与代谢性骨病

二甲双胍与安慰剂联合胰岛素类似物对2型糖尿病患者骨密度及骨小梁评分的影响:一项随机安慰剂对照试验

The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial.
PubMed 文献 · Osteoporos Int · 2018-07-19

该研究为Copenhagen胰岛素与二甲双胍治疗试验的子研究,纳入407例2型糖尿病患者,随机接受二甲双胍或安慰剂联合不同胰岛素方案治疗18个月。结果显示两组在脊柱和髋部骨密度及骨小梁评分上均无显著组间差异,但两组骨小梁评分从基线至18个月均显著下降。

要点

  • 二甲双胍与安慰剂相比,对2型糖尿病患者脊柱和髋部骨密度及骨小梁评分无显著影响。
  • 两组骨小梁评分从基线至18个月均显著下降,二甲双胍组下降0.041,安慰剂组下降0.046。
  • 脊柱和全髋骨密度从基线至18个月无显著变化。

核心结论

  • 18个月二甲双胍治疗与安慰剂相比,对2型糖尿病患者脊柱和髋部骨密度及骨小梁评分无显著影响,两组骨小梁评分均显著下降。

研究设计与样本

  • 本研究为Copenhagen胰岛素与二甲双胍治疗试验的子研究,该试验为多中心、随机、18个月、安慰剂对照、双盲试验,比较二甲双胍与安慰剂联合不同胰岛素方案治疗2型糖尿病患者。
  • 本子研究共纳入407例患者,采用双能X线吸收法在基线及18个月随访时评估脊柱和髋部骨密度及脊柱骨小梁评分。

主要发现

  • 骨密度和骨小梁评分均无组间差异。
  • 脊柱和全髋骨密度从基线至18个月无显著变化。
  • 调整性别、年龄、维生素D、吸烟、BMI、2型糖尿病病程、HbA1c和胰岛素剂量后,骨小梁评分的组间差异增大但仍无统计学意义。
  • HbA1c与骨小梁评分呈负相关(p=0.009),糖尿病病程更长与股骨颈骨密度相关(p=0.003),体重指数对髋部和股骨颈骨密度有正向影响(分别为p<0.001和p=0.045)。

关键数值与推荐

  • HbA1c与骨小梁评分负相关(p=0.009)。
  • 糖尿病病程更长与股骨颈骨密度相关(p=0.003)。
  • 体重指数对髋部骨密度(p<0.001)和股骨颈骨密度(p=0.045)有正向影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Some antihyperglycemic medications have been found to affect bone metabolism. We assessed the long-term effects of metformin compared with placebo on bone mineral density (BMD) and trabecular bone score (TBS) in patients with type 2 diabetes. Metformin had no significant effect on BMD in the spine and hip or TBS compared with a placebo. INTRODUCTION: Patients with type 2 diabetes mellitus (T2DM) have an increased risk of fractures despite a high bone mass. Some antihyperglycemic medications have been found to affect bone metabolism. We assessed the long-term effects of metformin compared with placebo on bone mineral density (BMD) and trabecular bone score (TBS). METHODS: This was a sub-study of a multicenter, randomized, 18-month placebo-controlled, double-blinded trial with metformin vs. placebo in combination with different insulin regimens (the Copenhagen Insulin and Metformin Therapy trial) in patients with T2DM. BMD in the spine and hip and TBS in the spine were assessed by dual-energy X-ray absorptiometry at baseline and after 18 months follow-up. RESULTS: Four hundred seven patients were included in this sub-study. There were no between-group differences in BMD or TBS. From baseline to 18 months, TBS decreased significantly in both groups (metformin group, - 0.041 [- 0.055, - 0.027]; placebo group - 0.046 [- 0.058, - 0.034]; both p < 0.001). BMD in the spine and total hip did not change significantly from baseline to 18 months. After adjustments for gender, age, vitamin D, smoking, BMI, duration of T2DM, HbA1c, and insulin dose, the TBS between-group differences increased but remained non-significant. HbA1c was negatively associated with TBS (p = 0.009) as was longer duration of diabetes, with the femoral neck BMD (p = 0.003). Body mass index had a positive effect on the hip and femoral neck BMD (p < 0.001, p = 0.045, respectively). CONCLUSIONS: Eighteen months of treatment with metformin had no significant effect on BMD in the spine and hip or TBS in patients with T2DM compared with a placebo. TBS decreased significantly in both groups. TRIAL REGISTRATION: ClinicalTrials.gov (NCT00657943).

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Nordklint AK, Almdal TP, Vestergaard P, et al. The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial. Osteoporos Int. 2018. PMID: 30027438. doi:10.1007/s00198-018-4637-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。